EDF1 Knockout HeLa Polyclonal Cells are a polyclonal population of HeLa cells in which the EDF1 gene has been disrupted by CRISPR/Cas9-mediated genome editing. This product provides a heterogeneous loss-of-function model that preserves the diversity of editing events, minimizing clonal bias and enhancing the reproducibility of pooled functional analyses. As a ready-to-use knockout pool, these cells are optimized for investigating EDF1’s role in transcriptional regulation, signaling crosstalk, and cellular processes such as proliferation and migration. The polyclonal format is particularly suited for high-throughput screens and pathway dissection.
The host HeLa cell line is a human cervical adenocarcinoma line harboring human papillomavirus type 18 (HPV18) and exhibiting an aneuploid karyotype. As transformed cancerous epithelial cells, HeLa cells are a cornerstone of in vitro cancer research, commonly employed in studies of oncogenic signaling, drug sensitivity, and gene function. Their robust growth and well-characterized transcriptome make them an ideal platform for examining the consequences of EDF1 knockout in a malignant context, allowing direct assessment of how this transcriptional coactivator influences cancer cell phenotypes.
EDF1 (Endothelial Differentiation Factor 1) is a transcriptional coactivator that bridges sequence-specific transcription factors, notably PPARgamma, to the basal transcription machinery through direct interaction with TBP and the TFIID complex. Its activity is modulated by calcium/calmodulin signaling and upstream cues such as Notch intracellular domain, VEGF, and PPARgamma ligands. This enables EDF1 to regulate the expression of PPARgamma-responsive metabolic genes (FABP4, CD36) and endothelial differentiation markers (VEGFR2, eNOS), thus integrating metabolic and developmental signals. By associating with calmodulin, EDF1 connects calcium-responsive pathways to transcriptional outputs, serving as a hub in networks controlling lipid metabolism and endothelial specification.
In HeLa cells, disruption of EDF1 abrogates its coactivator function, thereby perturbing transcriptional programs that drive cancer cell proliferation, migration, and metabolic adaptation. This model allows dissection of how EDF1-mediated coactivation of PPARgamma and other factors contributes to oncogenic phenotypes, independent of endothelial lineage contexts. Given the aneuploid nature of HeLa cells, this knockout pool also facilitates exploration of the interplay between genomic instability and EDF1-dependent transcriptional regulation, with implications for understanding tumor biology.
This polyclonal knockout cell pool supports a range of applications, including studies on endothelial gene regulation, PPARgamma coactivation mechanisms, and metabolic disorder modeling. Researchers can validate gene expression changes via western blotting, RT-qPCR, and RNA-seq, and assess transcriptional activity using PPARgamma reporter assays. Co-immunoprecipitation can confirm EDF1 interactions with TBP, calmodulin, or PPARgamma, while proliferation and migration assays measure functional consequences in cancer. These cells are also valuable for drug target validation and calcium/calmodulin signaling investigation. For further information, contact Ascent Research.
